Transfusion of granulocyte rich buffy coats to neutropenic patients

Abstract

Granulocyte rich buffy coats were transfused to infected neutropenic patients when leukapheresis donors were not available. Efficacy of transfusions was evaluated from data supplied by hospitals administering them. Buffy coats separated from ACD blood contained a mean of 4.9 X 10(8) granulocytes. Fifty-seven patients received a course consisting of a mean of 3.8 transfusions. Of these, 27 received a mean of 17.5 units per transfusion and had a survival rate of 44.4%, which was not significantly different from the 50.0% found in 30 who received a mean of 11.1 units per transfusion. No significant difference in survival rate was found between 31 patients with acute leukemia and 26 with other disorders or 38 patients with positive and 19 with negative cultures. Finally, no significant difference in survival rate was noted between patients who received a course of greater than or equal to four transfusions or less than or equal to three transfusions in any of the above groups. Survival rates were less than those generally reported following similar courses of leukapheresis units. Buffy coat transfusions consisting of a mean of approximately 17.5 units as produced during this study have therefore been shown to be not generally beneficial. The increased survival seen in some studies utilizing leukapheresis products may relate in part to the larger number of granulocytes they contained. Greater benefit from buffy coat transfusions might result if the number of granulocytes infused were increased. Evaluation of possible efficacy associated with transfusions of increased numbers of buffy coat units further enriched with granulocytes may be justified when leukapheresis donors are not available.

The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer

“…Such perturbations may occur as a consequence of the loss of tumor suppressor gene function, including the loss of responsiveness to growth suppressing molecules such as TGF-bs (Reiss, 1997;White, 1998). Resistance to Figure 4 In situ hybridization in the normal pancreas.…”

The role of TGF-β and Wnt signaling in gastrointestinal stem cells and cancer

“…High levels of TGF-b expression are correlated with advanced clinical stage of the tumor (Reiss, 1997;Gold, 1999). Tumor-derived TGF-b could contribute to tumor growth indirectly by suppressing immune surveillance or stimulating production of angiogenic factors.…”

TGF-β, Neuronal Stem Cells and Glioblastoma

“…Its tumorsuppressive function is lost in many tumor-derived cell lines (Reiss, 1997(Reiss, , 1999. The malignant phenotype of transformed and tumor-derived cells in culture is activated further by TGF-b.…”